INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 453m ago
HOUSE PTR53m ago
SEC 13F53m ago
ROBINHOOD CHAIN53m ago
SEC FORM 4/Option exerciseVerified data

Onyia Jude reported NBIX

Chief Scientific Officer · NEUROCRINE BIOSCIENCES INC · NEUROCRINE BIOSCIENCES INC — Restricted Stock Unit

Side
M
Value
—
Shares
4,426
Price
—
Executed
Nov 29, 2025
Disclosed
Dec 2, 2025
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Nov 29 executedDec 2, 2025 disclosed

NBIX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NBIX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    RE
    Roberts EiryChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    8,314 sh
    		Nov 4, 2026Nov 5, 2026
    traded Nov 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RE
    Roberts EiryChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    1,506 sh
    		Nov 4, 2026Nov 5, 2026
    traded Nov 4, 2026
    		+1dSEC FORM 4

    Evidence

    13
    DI
    Delaet IngridChief Regulatory Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    4,483 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    18
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$130K
    826 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    27
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$330K
    2,112 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    15
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    3
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award · 10b5-1 plan
    		A—
    5,020 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CJ
    Cooke JulieChief Human Resources Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    19
    CJ
    Cooke JulieChief Human Resources Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    21
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,914 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    25
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$363K
    2,311 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    15
    DI
    Delaet IngridChief Regulatory Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$378K
    2,419 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding · 10b5-1 plan
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    3
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award · 10b5-1 plan
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding · 10b5-1 plan
    		F$423K
    2,709 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    0
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    3,194 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    21
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$333K
    2,154 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    6
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M$138K
    3,194 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    12
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Gift
    		G—
    2,441 sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001894425-25-000010
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 29, 2025
    Published
    Dec 2, 2025
    Ingested by INSIDER
    Nov 5, 04:30 UTC
    Last re-read
    Nov 5, 04:30 UTC

    Extracted facts

    Filer
    Onyia Jude
    Role
    Chief Scientific Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    NEUROCRINE BIOSCIENCES INC — Restricted Stock Unit
    Ticker
    NBIX
    Shares
    4,426
    Price per share
    $0
    Execution date (reported)
    Nov 29, 2025
    Owned after transaction
    0 shares
    Days from execution to publication
    3

    What this establishes

    Onyia Jude filed this Form 4 reporting a option exercise of NBIX on Nov 29, 2025. It became public on Dec 2, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Onyia Judecik:0001894425
    Issuer
    NEUROCRINE BIOSCIENCES INCcik:0000914475

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.